In a recent article (1), on page 46, first paragraph, lines 1-7: The text reads, "All 4 trials with quality-of-life outcomes showed that ablation improved MLHFQ [Minnesota Living with Heart Failure Questionnaire] scores, although the findings in 1 trial were not statistically significant. Overall, the improvement in MLHFQ scores observed in the AF [atrial fibrillation] ablation group relative to the drug therapy group was statistically significant (mean difference, Ϫ9.02 points [CI, Ϫ19.75 to 1.71 points])". However, the result for this particular clinical outcome was not statistically significant because the difference in the pooled estimate crosses the 0; as a result, the null hypothesis is rejected, making the analysis statistically nonsignificant. We presented those results only with a descriptive purpose to show a nonsignificant improvement in MLHFQ scores with catheter ablation.
In Figure 4 on page 47, the labels at the bottom of the forest plot demonstrating the pooled analysis of MLHFQ scores indicate that the negative scores favor no ablation instead of favoring ablation. The forest plot horizontal axis was labeled in error and must be the other way around, demonstrating negative scores favoring ablation. That is, the implication that the MLHFQ scores were improved by ablation was indeed correct, but the figure was incorrectly labeled.
The authors sincerely apologize for these errors. The online version of the article has been corrected to reflect these changes. 
Abetalipoproteinemia From Previously Unreported Gene Mutations
Background: Abetalipoproteinemia is a rare, autosomal recessive disorder that requires mutations in both alleles of the gene for microsomal triglyceride transfer protein (MTTP). The mutations cause improper packaging and secretion of lipoprotein particles that contain apolipoprotein B from enterocytes and hepatocytes. These abnormalities lead to intracellular lipid retention and reductions in plasma levels of chylomicrons and very-low-density lipoprotein. Lipids and lipid-soluble vitamins are therefore malabsorbed, which causes retinal degeneration and eventual blindness followed by neuropathy and coagulopathy that are often severe and debilitating. Clinical diagnosis of abetalipoproteinemia is difficult because of its similarity to 2 related conditions, hypobetalipoproteinemia and chylomicron retention disease ( Figure 1 ). Definitive diagnosis involves identifying the mutations in both alleles of the MTTP gene (1-4).
Objective: To describe a patient with abetalipoproteinemia caused by previously unrecognized mutations in MTTP.
Case Report: An otherwise-healthy 18-year-old woman presented with mild vision impairment and inability to see in dim light (nyctalopia). As an infant, the patient was diagnosed with failure to thrive, easy vomiting, and fatty stools. Results of diagnostic laparotomy at 3 months of age were normal. Dietary fats were eliminated by trial and error, and she developed normally except for night blindness first noticed at age 4 years and a mild bleeding diathesis that was recognized later. ). Free fatty acid levels and thyroid function were normal. Blood smears showed pronounced acanthocytosis, and there were signs of increased erythrocyte turnover rates (reticulocyte count, 2.2%, and hemoglobin A 1c level, 3.8%).
Mild hepatic steatosis was noted on ultrasonography; gastroduodenoscopy showed a marked, pale-yellow discoloration of the small-bowel mucosa, about which we have written The combination of decreased plasma levels of chylomicrons and VLDL can be produced by defects in the gene for either MTTP (*) or apolipoprotein B (APOB) ( †). Defects in MTTP lead to abetalipoproteinemia, and defects in APOB lead to hypobetalipoproteinemia. Defects in the gene for secretion associated Ras related guanosine triphosphatase 1B (SAR1B) (indicated by a double dagger) impair production of chylomicrons but not VLDL and lead to chylomicron retention disease. apo = apolipoprotein; MTTP = microsomal triglyceride transfer protein; TG = triglycerides; VLDL = very-low-density lipoprotein.
previously (5) . Results of duodenal biopsies confirmed lipidfilled vacuoles in the enterocytes. Electromyography showed polyneuropathy. Bone densitometry revealed osteopenia but not osteomalacia or rickets. All of these findings were compatible with abetalipoproteinemia.
The patient was the only child of nonconsanguineous parents and the only person affected in either family. Nextgeneration sequencing was done on the coding exons and at least 20 flanking nucleotides of 29 genes involved in lipoprotein metabolism (including APOB, PCSK9, ANGPTL3, MTTP, MYLIP, and SAR1B) to detect point mutations and small deletions or insertions. Further analysis was done to identify large deletions or duplications. The patient's DNA revealed a variant in intron 4 of MTTP, c.393 + 1A>T, which affects the 3' acceptor splice site, and a heterozygous complete deletion of MTTP (reference sequence NM_000253.3). One variant was confirmed in the DNA of the patient's mother and the other in the DNA of her father. To our knowledge, neither variant has been described before or identified in index cases in our laboratory or in the approximately 120 000 alleles of the Exome Aggregation Consortium database (http://exac.broadinstitute .org).
Discussion: The patient is being treated with a low-fat diet; intravenous supplementation of essential fatty acids; and largedose lipophilic vitamins, including intravenous doses when necessary. We expect that this regimen will slow disease progression and help preserve neurologic, ophthalmologic, and bone function (3).
Population Trends in Intensive Care Unit Admissions in the United States Among Medicare Beneficiaries, 2006 -2015
Background: Admission to the intensive care unit (ICU) is costly and strains health system resources (1). Accurate estimates of population-level ICU admission rates could aid in disaster planning, training a suitable critical care workforce, and targeting policy interventions to reduce admissions that are low-value or discordant with patient preferences.
Objective: To overcome limitations of prior estimates of ICU use (2) by evaluating nationally representative data and examining geographic differences in admission incidence.
Methods and Findings: Using the entire Medicare Provider Analysis and Review file, we evaluated all hospitalizations involving acute and ICU care (including cardiac intensive care but not intermediate care [3] ) between 2006 and 2015 among Medicare fee-for-service beneficiaries aged 65 years or older. We calculated person-years of coverage using the Medicare Provider Analysis and Review Denominator file.
We used data from all 50 states; Washington, DC; and Puerto Rico to assess the relationship between the incidence of ICU admissions and the number of total ICU beds (that is, medical, surgical, and cardiac), estimated using the American Hospital Association Annual Survey Database. For amongstate comparisons, we adjusted ICU admission rates for each state's age and sex distributions using 2010 U.S. Census data. We tested changes over time for counts and proportions using simple Poisson regression and the 2 test for trend, respectively. We reported CIs around count estimates using 95% 2-sided Poisson values. Analyses were performed using SAS (SAS Institute) and the R programming language (R Foundation for Statistical Computing). The Institutional Review Board of the University of Pennsylvania approved this study.
We analyzed claims from 88 402 008 hospitalizations, 14 787 690 (16.7%) of which were associated with ICU care during 289 391 446 person-years of coverage. The ICU admission rate was 6117 per 100 000 person-years (95% CI, 5965 to 6272) in 2006 and decreased to 4247 per 100 000 person-years (CI, 4120 to 4377) in 2015 (P < 0.001). The proportion of hospitalizations that included ICU care also decreased during this period from 17.0% to 16.3% (P < 0.001).
In 2015, we observed a nearly 3-fold difference among state-level ICU admission rates, which ranged from 2117 per 100 000 person-years (CI, 2027 to 2209) in Hawaii to 6312 per 100 000 person-years (CI, 6157 to 6470) in Mississippi. Intensive care unit admission rates decreased in all states except Nebraska, where they increased from 3798 per 100 000 person-years (CI, 3678 to 3921) in 2006 to 3992 per 100 000 person-years (CI, 3869 to 4118) in 2015.
In 2006, the state-level ICU admission rate and number of total beds were positively associated with up to approximately 20 ICU beds per 100 000 person-years ( Figure 1) , with no clear association at greater bed capacities. The association between ICU admissions and number of beds was more strongly positive in 2015, with a monotonically increasing relationship except for 2 regions (Washington, DC, and North Dakota) with many beds and few admissions. Although the national ICU bed count increased by 11.4% between 2006 and 2015, state-level changes ranged from Ϫ38.1% (Rhode Island) to 54.4% (Washington). No association was observed between the percentage of change in ICU beds and admissions across states ( Figure 2) .
Discussion: This nationally representative study shows that ICU admission rates among Medicare fee-for-service beneficiaries have decreased in the past decade. Large, state-level differences in ICU admission rates were partially associated with ICU bed availability, whereas temporal changes in admission rates were not associated with bed growth. This observation is consistent with previously reported heterogeneity in bed growth and occupancy at the state (4) and hospital (5) levels.
Limitations of this study include the use of Medicare Provider Analysis and Review data, which do not represent populations enrolled in other insurance plans or those without insurance. We also did not adjust for patient-level factors, such as comorbidities, clinician practice patterns, or market competition, which would probably explain some differences in ICU admission rates.
Policy and population health strategies to promote highvalue care for Medicare fee-for-service beneficiaries requiring ICU services probably vary among states. The United States has more ICU beds per capita than many peer nations (2); however, bed availability is not the sole driver of ICU admissions and its effects also vary across states. Institution of federal policies governing critical care workforce training, reimbursements for critical care services, and state-level approvals of certificates of need will thus require more local and granular data. 
